Background: Midbrain atrophy is a well-known feature of progressive supranuclear palsy (PSP). Some clinical features of vascular parkinsonism (VP) such as pseudobulbar phenomena, lower body predominance and early postural instability suggest that the brainstem could be associated with VP. The aim of this study was to determine whether midbrain atrophy was present in patients with VP. Methods: We measured the midbrain (Amd) and pons area (Apn) of 20 patients with VP, 15 patients with probable PSP and 30 patients with idiopathic Parkinson’s disease (IPD). The Amd and Apn were measured on mid-sagittal T1-weighted MRI scans using a computerized image analysis system. Results: For the Amd, the patients with VP (99.86 mm2) and PSP (87.30 mm2) had significantly smaller areas than the patients with IPD (130.52 mm2). For the Apn, there was a significant difference only between the VP (407.23 mm2) and the IPD (445.05 mm2) patients. The Amd/Apn ratios of the patients with VP (0.245) and PSP (0.208) were significantly smaller than in the patients with IPD (0.292). Conclusions: Our study shows that brainstem atrophy often occurs in patients with VP and the midbrain is more vulnerable than the pons to atrophic changes.

Keywords:
Vascular parkinsonism, Progressive supranuclear palsy, MRI, Atrophy, Brainstem
1.
Critchley M: Arteriosclerotic parkinsonism. Brain 1929;52:23–83.
2.
Demirkiran M, Bozdemir H, Sarica Y: Vascular parkinsonism: a distinct, heterogenous clinical entity. Acta Neurol Scand 2001;104:63–67.
3.
Winikates J, Jankovic J: Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98–102.
4.
Thanvi B, Lo N, Robinson T: Vascular parkinsonism – an important cause of parkinsonism in older people. Age Ageing 2005;34:114–119.
5.
Cosottini M, Ceravolo R, Faggioni L, Lazzarotti G, Michelassi MC, Bonucelli U, Murri L, Bartolozzi C: Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand 2007;116:37–42.
6.
Kato N, Arai K, Hattori T: Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003;210:57–60.
7.
Yagishita A, Oda M: Progressive supranuclear palsy: MRI and pathological findings. Neuroradiology 1996;38:S60–S66.
8.
Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, Furui S, Shimizu T, Uchigata M, Matsumura K, Sonoo M, Sakai M, Takada K, Harasawa A, Takeshita K, Kohtake H, Tanaka H, Suzuki S: New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005;64:2050–2055.
9.
Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, Lanza P, Barone P, Morgante L, Zappia M, Aguglia U, Gallo O: MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246:214–221.
10.
Bastos Leite AJ, van der Flier WM, van Straaten EC, Scheltens P, Barkhof F: Infratentorial abnormalities in vascular dementia. Stroke 2006;37:105–110.
11.
Sung YH, Park KH, Lee YB, Park HM, Shin DJ, Park JS, Oh MS, Ma HI, Yu KH, Kang SY, Kim YJ, Lee BC: Midbrain atrophy in subcortical ischemic vascular dementia. J Neurol 2009;Epub ahead of print.
12.
Rektor I, Rektorova I, Kubova D: Vascular parkinsonism – an update. J Neurol Sci 2006;248:185–191.
13.
Gibb WR, Lees AJ: The relevance of Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745–752.
14.
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.
15.
Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP parkinsonism. Brain 2005;128:1247–1258.
16.
Zijlmans JC, Daniel SE, Hughes AJ, Révész T, Lees AJ: Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004;19:630–640.
17.
Ondo WG, Chan LL, Levy JK: Vascular parkinsonism: clinical correlates predicting motor improvement after lumbar puncture. Mov Disord 2002;17:91–97.
18.
Okuda B, Kawabata K, Tachibana H, Kamogawa K, Okamoto K: Primitive reflexes distinguish vascular parkinsonism from Parkinson’s disease. Clin Neurol Neurosurg 2008;110:562–565.
19.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol 1987;149:351–356.
20.
Tsui WH, Rusinek H, Wan Gelder P, Lebedev S: Analyzing multi-modality tomographic images and associated regions of interest with MIDAS. SPIE Medical Imaging: Imaging Processing 2001;4322:1725–1734.
21.
Lantos PL: The neuropathology of progressive supranuclear palsy. J Neural Transm Suppl 1994;42:137–152.
22.
Aiba I, Hashizume Y, Yoshida M, Okuda S, Murakami N, Ujihira N: Relationship between brainstem MRI and pathologic findings in progressive supranuclear palsy: study in autopsy cases. J Neurol Sci 1997;152:210–217.
23.
Masucci EF, Borts FT, Perl SM, Wener L, Schwankhaus J, Kurtzke JF: MR vs. CT in progressive supranuclear palsy. Comput Med Imaging Graph 1995;19:361–368.
24.
Warmuth-Metz M, Naumann M, Csoti I, Solymosi L: Measurement of the midbrain diameter on routine magnetic resonance imaging. Arch Neurol 2001:58:1076–1079.
25.
Schonfeld SM, Globe LI, Sage JI, Sager JN, Duvoisin RC: Computed tomographic findings in progressive supranuclear palsy: correlation with clinical grade. Move Disord 1987;2:263–278.
26.
Nakane M, Teraoka A, Asota R, Tamura A: Degeneration of the ipsilateral substantia nigra following cerebral infarction in the striatum. Stroke 1992;23:328–332.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.